[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

617-341-6777

Email address

medicalinfo@vrtx.com

Condition

Type 1 Diabetes

Treatment type

Interventional

Investigational product

VX-264

Phase

Phase 1/Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

ClinicalTrials.gov identifier

NCT05791201

Study number

VX22-264-101

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

  1. Clinical history of T1D with greater than (>) 5 years duration
  2. Participant is on a stable diabetic treatment
  3. Consistent use of continuous glucose monitoring (CGM) for at least 4 weeks before Screening and willingness to use CGM for the duration of the study Key
Exclusion criteria

  1. Prior islet cell transplant, organ transplant, or cell therapy Other protocol defined Inclusion/Exclusion criteria may apply.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site